Lithium orotate

A lithium salt sold as a dietary supplement, marketed for mood and brain health; it is not FDA-approved for any use.

psilodex.org/m/lithium-orotate · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: Not stated in label or references

Named in state rules?

UnsettledColorado

UnsettledOregon

PendingNew Mexico

Cite asPsilodex, “Lithium orotate”, v2026.10.05. psilodex.org/m/lithium-orotate

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

Not FDA-approved

Other safety

A case report describes mild acute lithium toxicity after an overdose of a lithium orotate supplement.

About the medication itself, separate from any interaction with psilocybin.

Sources [2]

01 Interaction with psilocybin

Not studied with psilocybin; prescription lithium with classic psychedelics was linked to seizures, but whether this applies at supplement doses is unknown.

Detail There are no psilocybin data for lithium orotate. Lithium orotate is thought to dissociate and be absorbed as the lithium ion, with pharmacokinetics comparable to lithium carbonate (Hajek 2026). Supplements typically supply far less elemental lithium than prescription doses (Pauzé 2007). With prescription-type lithium, 47% of 62 online reports of lithium with a classic psychedelic described seizures (Nayak 2021). Whether this applies at supplement doses is unknown. Sources [1][2][3]

Human data with psilocybin: No data on this medication itself; related drugs studied (see text)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Unsettled · 2.2(A)(6)–(7)

Rule 2.2(A)(6)–(7) names "lithium" without stating its form, dose or prescription status, so whether it covers low-dose lithium orotate supplements is unsettled. If the provision covers it: Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).

2.2(A)(6)–(7) · Facilitator licensees

Colorado · checked 2026-10-04

OROAR 333-333

Unsettled · 333-333-5050(3)(a)

Oregon's required Client Information Form names lithium without stating its form or dose, so whether it covers low-dose lithium orotate supplements is unsettled. If it does: a client who has taken lithium in the last 30 days may not participate in an administration session.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Hajek T, Munthe S, Licht RW. Lithium orotate: distinct compound or simply Li(+) after administration? Br J Psychiatry 2026. — Abstract: "acid-base chemistry predicts that LiO will be largely protonated in the stomach, causing it to dissociate and be absorbed as Li+; (c) experimental studies indicate that LiO and LiC have comparable pharmacokinetics after oral administration"
Pauzé DK, Brooks DE. Lithium toxicity from an Internet dietary supplement. J Med Toxicol 2007;3(2):61–62. — Abstract: "120 mg of lithium orotate [3.83 mg of elemental lithium per 100 mg of (organic) lithium orotate compared to 18.8 mg of elemental lithium per 100 mg of (inorganic) lithium carbonate]" "Chronic lithium toxicity from ingestion of this product is also of theoretical concern."
Nayak SM, Gukasyan N, Barrett FS, et al. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures. Pharmacopsychiatry 2021.

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →